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modelling substrate and ligand binding
An array of molecular simulation techniques, combined with 
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The main protease (Mpro) of SARS-CoV-2 is central to viral maturation and is a promising drug target, but
little is known about structural aspects of how it binds to its 11 natural cleavage sites. We used
biophysical and crystallographic data and an array of biomolecular simulation techniques, including
automated docking, molecular dynamics (MD) and interactive MD in virtual reality, QM/MM, and linear-
scaling DFT, to investigate the molecular features underlying recognition of the natural Mpro substrates.
We extensively analysed the subsite interactions of modelled 11-residue cleavage site peptides,
crystallographic ligands, and docked COVID Moonshot-designed covalent inhibitors. Our modelling
studies reveal remarkable consistency in the hydrogen bonding patterns of the natural Mpro substrates,
particularly on the N-terminal side of the scissile bond. They highlight the critical role of interactions
beyond the immediate active site in recognition and catalysis, in particular plasticity at the S2 site.
Building on our initial Mpro-substrate models, we used predictive saturation variation scanning (PreSaVS)
to design peptides with improved affinity. Non-denaturing mass spectrometry and other biophysical
analyses confirm these new and effective ‘peptibitors’ inhibit Mpro competitively. Our combined results
provide new insights and highlight opportunities for the development of Mpro inhibitors as anti-COVID-
19 drugs.1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is the etiological agent of coronavirus disease 2019 (COVID-
19) that caused the World Health Organization to declare
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a single-stranded positive-sense RNA virus, is hydrolysis of its
polyproteins pp1a and pp1ab. Most of the cleavage events—at
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View Article Online(Mpro; 3 chymotrypsin-like or 3CL proteinase, 3C-like protease,
3CLpro; or non-structural protein 5, Nsp5).
Mpro is a nucleophilic cysteine protease, which in solution is
predominantly homodimeric. Each protomer consists of three
domains, and the active site contains a cysteine–histidine
catalytic dyad, Cys-145 and His-41, located near the dimer
interface.2 SARS-CoV-2 Mpro is 96% identical to the Mpro of
SARS-CoV, which causes SARS.3 Dimerisation of Mpro is
proposed as a prerequisite for catalysis: the N-terminus of one
protomer contributes part of the active site of the other.4
Indeed, the monomeric form of SARS-CoVMpro is reported to be
inactive.5 Evidence from non-denaturing mass spectrometry
(MS)-based assays indicates that Mpro monomers are not only
inactive (at least with tested substrates), but do not bind 11-mer
substrates with high affinity.6
SARS-CoV-2 Mpro and SARS-CoV Mpro have similar substrate
specicities, both recognizing the motif: [P4:Small] [P3:X]
[P2:Leu/Phe/Val/Met] [P1:Gln]Y[P10:Gly/Ala/Ser/Asn], “Small”
denoting Ala, Val, Pro or Thr; “X” any residue; and “Y” the
scissile amide (Fig. 1).7,8 In part, because such sequences are not
known to be recognised by any human protease, Mpro repre-
sents an attractive drug target.4 Although no clinically approved
Mpro drugs are available, small molecule inhibitors and pepti-
domimetics have been designed to inhibit SARS-CoV Mpro and,
more recently, SARS-CoV-2 Mpro.11,12 Indeed, a covalent Mpro
inhibitor from Pzer has recently entered clinical trials.13,14
Multiple crystallographic and computational modelling
studies concerning the Mpro mechanism15–18 and inhibition areFig. 1 Substrates processed by SARS-CoV-2 Mpro. (a) The 11 SARS-CoV-
s11; positively/negatively charged residues are blue/red, respectively; hist
yellow. (b) Comparison between the 11 substrate sequences (generated b
highly conserved Leu at P2. (c) View of an energy minimisedmodel, built u
s05 (dark grey sticks); subsites S4–S40 are labelled. The oxyanion hole fo
cyan. (d) The reaction catalysed by Mpro exemplified by s01. Substrate re
© 2021 The Author(s). Published by the Royal Society of Chemistryavailable;19–24 the CORD-19 database25 documents many such
studies. It is proposed that during Mpro catalysis, His-41
deprotonates the Cys-145 thiol, which reacts with the carbonyl
of the scissile amide to give an acyl-enzyme intermediate. This
intermediate is stabilised by a hydrogen bond network that
holds the scissile amide carbonyl in an ‘oxyanion hole’. The C-
terminal part of the product likely leaves the active site at this
stage. The acyl-enzyme intermediate is subsequently hydrolysed
with loss of the N-terminal product regenerating active Mpro.
Computational and mechanistic studies on SARS-CoV Mpro26–29
and SARS-CoV-2 Mpro30–32 suggest that in the resting state His-41
and Cys-145 are likely neutral and that the protonation states of
nearby histidines (e.g.His-163, 164, and 172) affect the structure
of the catalytic machinery—although it has been suggested in
SARS-CoV Mpro that the protonation state of the catalytic dyad
may change in the presence of an inhibitor or substrate.33 A
different picture has been obtained from neutron crystallo-
graphic studies, which indicate that an ion pair form of the dyad
is favoured at pH 6.6.34 While neutron crystallography, in
principle, enables the direct determination of hydrogen atom
positions, questions remain about how pH and the presence of
active site-bound ligands inuence the precise—and likely
dynamic—protonation state(s) of the dyad.
Important questions remain regarding Mpro catalysis,
including to what extent the active site protonation state, solvent
accessibility, induced t, and substrate sequence inuence
activity. The lack of this knowledge makes it difficult to carry out
effective computational studies on Mpro catalysis and inhibition.2 Mpro cleavage sites, and the corresponding 11-residue peptides, s01–
idine is purple; residues with polar sidechains are green; and cysteine is
y WebLogo)9 highlighting the completely conserved Gln at P1 and the
sing apoMpro (PDB: 6yb7, light grey surface),10 of Mpro complexed with
rmed by the Mpro backbone NHs of Gly-143, Ser-144 and Cys-145 is
sidues important in recognition (see main text) are highlighted.
Chem. Sci., 2021, 12, 13686–13703 | 13687

























































































View Article OnlineWith the aim of helping to combat COVID-19, in April 2020
we embarked on a collaborative effort involving weekly virtual
meetings, initially to investigate the relationship between Mpro
substrate selectivity and activity. We employed an array of
classical molecular mechanics (MM) and quantum mechanical
(QM) techniques, including non-covalent and covalent auto-
mated docking, molecular dynamics (MD) simulations, density
functional theory (DFT), combined quantum mechanics/
molecular mechanics (QM/MM) modelling, and interactive
MD in virtual reality (iMD-VR). Our results provide consensus
atomic-level insights into the interactions of Mpro with 11-
residue peptides derived from the 11 natural cleavage sites
(named “s01” to “s11”, in order of occurrence in the viral pol-
yprotein, Fig. 1a). The identication of key interactions between
Mpro and its substrates, together with analysis of fragment/
inhibitor structures,35,36 led to the design of peptides proposed
to bind more tightly than the natural substrates, several of
which inhibit Mpro. The results are freely available via GitHub
(https://github.com/gmm/SARS-CoV-2-Modelling).
2. Results and discussion:
understanding substrate binding and
recognition
2.1 Protonation state of the catalytic dyad
The protonation state of the dyad following substrate binding
was studied with s01-bound (Fig. 1a) Mpro37 using QM/MM
umbrella sampling simulations at the DFTB3/MM and uB97X-
D/6-31G(d)/MM levels of theory (Section S1.1†). The proton-
ation states of nearby histidines were also evaluated (Table S2.1
and Fig. S2.5, S2.6†).
His-41 was treated as Nd-protonated in the neutral state of
the dyad, as reported by Pavlova et al. to be preferred for both
uncomplexed and N3 inhibitor-bound Mpro based on MD
studies.30 The protonation state of the dyad-neighbouring His-
163, which interacts with Tyr-161, Phe-140 and the substrate
P1 Gln sidechain, was also studied. Three His-163 protonation
states were considered: (i) Nd-protonated, neutral (“HID”); (ii)
N3-protonated, neutral (“HIE”); and (iii) Nd and N3-protonated,
positively charged (“HIP”).38 For all three His-163 protonationFig. 2 QM/MM umbrella sampling of the proton transfer in the cata-
lytic dyad. Representation of the interactions of the Cys-145 thiolate in
the ion pair (IP) state from the (a) forwards and (b) backwards simu-
lations. (c) Free energy profile for interconversion of the neutral (N) and
ion pair states of the dyad in the HIE-163 system, from the combined
forwards and backwards QM/MM umbrella sampling MD simulations,
corrected to the uB97X-D/6-31G(d)/MM level of theory.
13688 | Chem. Sci., 2021, 12, 13686–13703states, the forward trajectories (neutral, N to ion pair, IP)
showed the anionic Cys-145 form to be stabilised solely by
interaction with positively charged His-41 (Fig. 2a and S2.2A–
C†), and the thiolate in an unreactive conformation for nucle-
ophilic attack. This suggests that such a zwitterionic state is
transient, with concerted proton transfer and simultaneous
nucleophilic attack of the thiolate onto the scissile amide
carbon being more likely than a stepwise mechanism.15 By
contrast, the backwards PT trajectories (from IP to N) showed
stabilisation of the Cys-145 thiolate by His-41 and the P1 Gln
backbone N–H, in the case of HID-163 and HIP-163 (Fig. S2.2E,
F†). For HIE-163, additional stabilisation comes from interac-
tions with the backbone N–H and the hydroxyl of the P10 Ser,
and an additional water that diffuses into the active site (Fig. 2b
and S2.2D†).
The zwitterionic state with HID-163 was less stable than the
neutral state and the zwitterionic states with HIE-163 and HIP-
163 (Fig. S2.1C†). This was due to perturbation of the interac-
tion network with Tyr-161 and Phe-140, suggesting that a Nd-
protonated His-163 is unlikely. Double protonation of His-163
results in a loss of both interactions in the forwards and back-
wards PT trajectories. Despite both HIP-163 and HIE-163 giving
similar PT free energy proles, the loss of these interactions
suggests HIP-163 is unfavourable for productive catalysis. These
QM/MM results therefore suggest that an N3-protonated neutral
His-163 is most likely. Along with conserving interactions with
Tyr-161 and Phe-140, an N3-protonated His-163 also formed
a hydrogen bond with the P1 Gln side chain (Fig. 2a and b), an
interaction not observed in PT trajectories with HID-163 and
HIP-163.
Considering that DFTB3 overestimates the proton affinity of
methylimidazole, it is expected that this method will over-
stabilise the zwitterionic state relative to the neutral state.39
To account for this, the backwards PT reaction with a Nd-
protonated His-163 was modelled at the uB97X-D/6-31G(d)/MM
level of theory. This showed the zwitterionic state was
24.3 kJ mol1 above the neutral state, an increase of
26.4 kJ mol1 compared to DFTB3/MM (Fig. S2.3†). Applying the
free energy difference between uB97X-D/6-31G(d) and DFTB3 at
each reaction coordinate value as a correction to the combined
QM/MM free energy prole in the case of HIE-163, the neutral
catalytic dyad is preferred, with the ion pair being 28.5 kJ mol1
higher in energy than the neutral state (Fig. 2c). Similar results
were obtained with a different QM approach (Fig. S2.4 and
associated ESI Movie†).2.2 Models of SARS-CoV-2 Mpro–substrate peptide complexes
To understand substrate specicity and to assess their relative
binding affinities, we constructed 11 models of SARS-CoV-2 Mpro
complexed with its cleavage site-derived substrates40 as 11-amino
acid peptides, from P6 to P50 (Section S1.2; Fig. 1a and S2.7†). We
refer to these peptides as ‘substrates’ as their hydrolytic sites are
all cleaved by Mpro (vide infra). The substrates were modelled in
crystallographic chain A of the Mpro dimer (PDB: 6yb7)10 with
a neutral dyad; unless otherwise stated, all Mpro residue numbers
and names in the following discussions refer to chain A. Initial© 2021 The Author(s). Published by the Royal Society of Chemistry

























































































View Article Onlinemodels were subjected to three independent explicit-solvent MD
simulations each of 200 ns.
Three of the 11 cleavage site-derived peptides (s01, s02, and
s05) were also modelled with interactive MD using virtual reality
(iMD-VR), as an alternative to comparative modelling and
traditional MD. iMD-VR provides an immersive 3D environment
for users to interact with physically rigorous MD simula-
tions.41–43 The three substrates were chosen because s01 and s02
have the highest relative efficiencies (of SARS-CoV Mpro) of all
substrates; while s05 has the second-lowest catalytic efficiency
but the same P2 and P1 residues as s01.44
Throughout both the explicit-solvent MD and implicit-
solvent iMD-VR simulations, all the substrates remained
tightly bound in the active site (Fig. S2.8–S2.11†). Substrate
backbone stability was maintained especially in the central
region, with only the N- and C-terminal residues showing
substantial exibility. Local sidechain uctuations were
present, notably at the solvent-facing P3 residue (Fig. 1c and
S2.9†). C-terminal P0-residues consistently uctuated more than
the N-terminal P-side residues, likely in part because of fewer
protein–substrate hydrogen bonds on the P0 side (vide infra).
2.2.1 Conserved hydrogen bond interactions. Crystallo-
graphic studies on SARS-CoV Mpro revealed the importance ofFig. 3 Interactions between SARS-CoV-2 Mpro and its substrates. (a) Mpr
annotated heat-map showing the frequency of each HB, with blue indica
cumulative explicit-solvent MD conducted per system. (c) Close-up of th
subsites S1, S2, S10 and S20 labelled. Different views of the S1 subsite are s
sidechain. Subsite surface colour corresponds to the hydrophilicity score,
blue, and amphiphilic subsites in turquoise. (d) Hydrophilicity map for th
blue) subtracted from the sum of hydrophobic interactions (yellow). Int
(Methods Section S1.5†).
© 2021 The Author(s). Published by the Royal Society of Chemistryhydrogen bonds in binding of substrate s01,37 which has the
same cleavage site sequence in SARS-CoV-2 (Fig. 1a). To inves-
tigate whether this was true for SARS-CoV-2 Mpro complexed
with its 11 substrates, we analysed the hydrogen bond (HB)
prevalence at each subsite in both explicit-solvent MD and
implicit-solvent iMD-VR simulations. Twelve HBs were consis-
tently identied (Fig. 3) and their distance and angular distri-
butions analysed (Fig. S2.12†).
In both explicit-solvent MD and iMD-VR simulations, all 11
substrates are primarily held in place by four consistently
formed backbone–backbone HBs: Glu-166 at S3 (2 & 3) and Thr-
26 at S20 (10 & 11; Fig. 3). Backbone HBs 1 and 12 further from
the cleavage site show greater variation between the MD and
iMD-VR studies. Although P1 Gln is conserved in all 11 Mpro
cleavage sites (Fig. 1a and b), HBs 5–9 formed in the S1 site are
observed less oen than 2, 3, 10 and 11, but outnumber other
sites. In both types of simulations, HB 8 from the Cys-145
backbone amide is consistently formed, suggesting that this
could play a fundamental role in catalysis. HB 8 forms part of
the oxyanion hole, which stabilises the tetrahedral intermediate
formed upon nucleophilic attack by Cys-145 Sg on the scissile
amide. Mpro's exquisite specicity for Gln at P1 is likely due to
formation of HB 6 with His-163, and to a lesser extent HB 7,o–substrate hydrogen bonds (HBs) exemplified by substrate s01. (b) An
ting highest frequency. Frames were extracted every ns from 600 ns of
e MD-generated bindingmode of SARS-CoV-2 Mpro-substrate s01 with
hown, emphasizing the deep S1 pocket that accommodates the P1 Gln
with hydrophobic subsites shown in yellow, hydrophilic subsites in dark
e 11 substrates calculated as the sum of hydrophilic interactions (dark
eractions were identified from substrate:Mpro frames using Arpeggio45
Chem. Sci., 2021, 12, 13686–13703 | 13689
Fig. 5 BigDFT analysis of Mpro–substrate interactions. (a) Heatmaps
showing QM interaction energies between 22 selected residues of
Mpro and s01, s02 and s05. (b) QM interaction networks where node
colour indicates interaction strength, from dark blue (strongest)
through green to yellow (weakest). Square nodes denote substrate,
while circular ones denote Mpro. The thickness and colour of the edges
show the fragment bond order between residues, a unitless measure
associated with bond strength and analogous to bond order; black is
strongest, orange is weakest.51 Interaction energies and bond orders
were computed using BigDFT and ensemble-averaged results of MD
snapshots.

























































































View Article Onlinealong with the narrowness of the S1 pocket accommodating the
Gln sidechain in an extended conformation.
2.2.2 Hydrophobicity analysis. Hydrophilicity analysis
shows that the S1 subsite is substantially hydrophilic in all 11
substrate–Mpro complexes, while S2 is consistently hydrophobic
(Fig. 3d). In accord with the MD-HB analysis (Fig. 3b), the
conservation of subsite interactions decreases further from the
cleavage site. Although S3 and S20 show a slight bias towards
hydrophilic interactions, none of the other subsites show
a consistent pattern.
2.2.3 Other non-covalent interactions. Beyond HBs, several
other interaction types are conserved across the substrates;
these were identied by running Arpeggio45 on snapshots
extracted from the explicit-solvent MD simulations (Fig. 4). Six
of the eight most common P1 interactions are present in most
(i.e., $9/11) substrates. This includes the previously described
HBs between the P1 backbone oxygen and the backbone NHs of
Cys-145 (HB 8) and Gly-143 (HB 9) that constitute the oxyanion
hole, as well as HB 6 (His-163) and HB 7 (Phe-140) that stabilise
the P1 Gln sidechain. In addition, interactions with Ser-144,
His-163, His-164, Glu-166 and, to a lesser extent, Phe-140 were
prevalent at P1. None of the other subsites show this level of
consistency in residue-level contacts, although some interac-
tions such as hydrophobic contacts with Met-49 and Met-165
were always present at P2. Furthermore, important stabilising
backbone HBs (HBs 2–3 between Glu-166 and P3; and HBs 10–
11 between Thr-26 and P20) were conserved in all substrates.
Finally, P0 interactions are less common than those on the P
side (Fig. 4). The same trend was found when docking s01, s02,
and s05 using iMD-VR, where P0 residues tended to be more
exible than P-side residues.
We further analysed the energetic contributions of each Mpro
residue using the Molecular Mechanics-Generalised Born
Surface Area (MM-GBSA) method (Section S2.3.1†),46–49 which
highlighted hotspot residues that were also recognised by
Arpeggio as conserved contacts.
2.2.4 Density functional theory analysis of the interaction
network. We performed linear-scaling DFT (BigDFT50)Fig. 4 Mpro–substrate contacts. Map of HBs and other non-covalent
interactions between the 11 substrates and Mpro from Arpeggio anal-
ysis of the most representative pose for each substrate generated by
MD. Dark blue indicates the interaction is formed by all 11 substrates at
that substrate position, while yellow indicates no substrates form this
interaction.
13690 | Chem. Sci., 2021, 12, 13686–13703calculations using representative snapshots extracted from
explicitly solvated MD trajectories of Mpro complexed with s01,
s02, and s05. By automatically decomposing large molecular
systems into coarse-grained subsets of atoms (or ‘fragments’) in
an unbiased manner,51 quantities like inter-fragment bond
order and interaction strengths, Econt, can be easily calculated
(Fig. 5a, S2.18–S2.21 and Section S2.4†). This analysis supports
the essential roles of Glu-166 and Thr-26, with interactions
observed in all three peptides s01, s02, and s05, consistent with
the HB analysis described earlier (Fig. 3). Gln-189 consistently
hydrogen-bonds with P2 (HB-4) in s01 and s05, but rarely in s02.
This weakening of HB-4 in P2 may be due the greater bulk of
Phe in s02 (Fig. 5b).
Conserved contacts are present in the three substrates
between Cys-145 and both P1 and P10 residues. Interactions
between His-41 and P2/P10 are observed for s01 and s05, and© 2021 The Author(s). Published by the Royal Society of Chemistry

























































































View Article Onlinebetween Glu-166 and P1/P3 (and, to some extent, to P4) for all
three substrates. This analysis singles out the character of s02,
which is dominated by the bulky character of its P2 Phe.
Substitutions at P2 may have a substantial effect on the inter-
action network close to the catalytic site. While the P side
exhibits an interconnected character especially from P1 to P4
(Fig. 5b), the network on the P0 side has a more linear character,
once again indicating that hotspot residues responsible for
binding are present on the P side. Distributions of Econt are
shown in Fig. S2.20.†
The following trends emerge from our studies on Mpro in
complex with models of its 11 substrates: (i) binding stability is
partly conferred by a series of HBs from P4 to P40, in particular
between the backbones of Mpro Glu-166 and Thr-26 and
substrate positions P3 and P20 respectively, as well as HBs
involving the conserved P1 Gln sidechain; (ii) substrate residues
N-terminal of the cleavage site (P side) form more, and more
consistent, contact interactions with Mpro compared to the P0
side, with interactions at Met-49, Gly-143, Ser-144, Cys-145, His-
163, His-164, Met-165 and Glu-166 being most conserved. We
conclude that the S1 and S2 pockets are prime targets for active
site substrate-competing inhibitor design due to their well-
dened hydrophilic character, large energy contributions to
substrate binding, and vital conserved hydrogen bonds in S1 for
substrate recognition.
2.2.5 Conformational plasticity in Mpro crystal structures.
Previous studies have compared the dynamics of ligand binding
sites across SARS-CoV-2, SARS-CoV and MERS-CoV Mpro.52 Here,
we investigated the conformational plasticity of the SARS-CoV-2
Mpro active site upon binding by comparing 333 Mpro:ligand co-
crystal structures obtained from Fragalysis53 to a reference apo
structure of Mpro, PDB entry 6yb7 (ref. 10) (Fig. 6). A high degree
of plasticity was observed at residues Thr-24, Thr-25, His-41,
Thr-45, Ser-46, Met-49, Asn-142, Met-165, Glu-166, Arg-188,
Gln-189 and Ala-191. Unsurprisingly, the S1 subsite isFig. 6 Analysis of the active site plasticity of 333 Mpro co-crystal structure
119, 121, 140–145, 163–168, 172, 181, 187–192) were chosen based on t
Mpro residues that contact any substrate. The violin plots show the distrib
ligand co-crystal structures53 and a reference uncomplexed structure (P
© 2021 The Author(s). Published by the Royal Society of Chemistryparticularly rigid, with almost no change in residue conforma-
tions across all 333 crystal structures.
In all cases, P1 Gln recognition is mainly driven by interac-
tions with Gly-143, Ser-144, Cys-145 (oxyanion hole) and His-163
and Phe-140. The S2 subsite, however, is highly exible, espe-
cially at Thr-45, Ser-46 and Met-49. Although P2 is conserved in
terms of hydrophobicity (Leu, Phe, Val), the S2 pocket is highly
exible and can adapt to accommodate functional groups of
varying sizes, including aliphatic and aromatic groups. The
outer regions of the active site (S3–S6 and S20–S50) vary in ex-
ibility, echoing our MD simulations.2.3 Monitoring of substrate sequence hydrolysis by mass
spectrometry
To rank the SARS-CoV-2 Mpro preferences for hydrolysis of the
11 cleavage sites, we monitored turnover of 11-mer peptides by
solid-phase extraction (SPE) coupled to mass spectrometry (MS).
Interestingly, aer the N-terminal autocleavage site s01, s11 was
the next preferred substrate for catalysis (Fig. S2.22†). Peptides
s06, s02, and s10 were hydrolysed less efficiently than s11. Slow
turnover was observed for s07 and s09. Evidence for low turn-
over of s05 was obtained aer prolonged incubation with Mpro
(9.56%) (Fig. S2.23†). Under our standard conditions, no
evidence for cleavage was observed for s03, s04, and s08.
We then examined turnover under non-denaturing MS
conditions using ammonium acetate buffer (Fig. 7a). Peptides
s01, s06, s08, s10 and s11 evidenced fast turnover. The level of
substrate ion depletion was >70% aer 1 min and >90% aer
6 min incubation. Peptides s02, s04 and s09 showed substrate
ion depletion from 35 to 45% aer 1 min incubation, >70%
depletion aer 6 min, and >90% depletion aer 12 min.
Peptides s03, s05 and s07 demonstrated slow turnover that was
below 50% aer 12 min incubation.s. Active site residues (residues 19, 21, 23–27, 41, 45, 46, 49, 54, 67, 69,
he MD analysis of the 11 substrate–Mpro models and correspond to all
utions of per-residue heavy atom RMSD values between the 333 Mpro–
DB 6yb7).10 Each Mpro subsite is colour-coded.
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Fig. 7 Non-denaturing mass spectrometry of Mpro substrate turnover.
(a) Substrate turnover versus incubation time as measured by non-
denaturing MS. Trend lines are given for visual guidance only. (b)
Examples of mass spectra showing normalized intensity in the m/z
region around the 16+ charge state of Mpro dimer (asterisk, *): (b1) pure
Mpro solution (5 mM); (b2) Mpro and s01 solution after 1 min incubation,
hashes (#) indicate the mass peaks corresponding to the s01 cleaved
fragments sequentially attached to theMpro dimer; note: the resolution
is not sufficient to distinguish between the N- or C-terminal fragments
(mass shifts of 617 and 593 Da, respectively); (b3) same solution as (b2)
after 6 min incubation; (b4) Mpro and s10 solution after 1 min incu-
bation, ‘N’ labels N-terminal fragment(s) attached (765 Da), ‘C’ labels
C-terminal fragment(s) attached (560 Da); (b5) Mpro and s03 solution
after 3 min incubation, ‘S’ labels intact substrate(s) attached, hashes (#)
label attached substrate fragments, but the N- and C-terminal frag-
ments cannot be distinguished (mass shift 644 and 566 Da, respec-
tively); (b6) same solution as (b5) after 9 min incubation.

























































































View Article OnlineIn the protein region of the mass spectra, complexes of the
Mpro dimer and the cleavage products were observed aer 1 min
of incubation for the fast-turnover substrates s01, s06, s08, s10
and s11, and also s02, s04 and s09 (Fig. 7b1–b4). For the slow-
turnover substrates s03, s05 and s07, only Mpro complexes
with intact substrates were observed aer 1 min incubation. For
longer incubation times, complexes between Mpro and the
products from these substrates emerged and increased in
abundance (Fig. 7b5 and b6).
The rank order of the substrates in part depends on the MS
method used, likely due to the differences in the buffers and
concentrations used: i.e., non-denaturing MS used ammonium
acetate buffer and an Mpro concentration of 5 mM, which is
higher than the 0.15 mM used in denaturing MS assays. Higher
concentrations of both enzyme and substrate in the non-
denaturing MS experiments explain the faster substrate turn-
over than seen with denaturing MS, especially as the concen-
tration of catalytically active Mpro dimer would be higher at
higher enzyme concentrations.6,54
Regardless of the MS method used, a clear trend is observed
in the catalytic turnover of the cleavage site-derived peptides.
The rank order of substrate preference under denaturing MS
conditions was s01 > s11 > s06 > s02 > s10 > s07 > s09 > s05
(Fig. S2.22 and S2.23†). Under non-denaturing conditions
(Fig. 7) turnover was: fast (s01, s11, s06, s10, and s08), medium
(s04, s02, and s09), and slow (s05, s03, and s07). Substrates s01,
s11 and s06 turned over fastest; while s07, s05 and s03 were slow
as measured by both methods. This is in broad agreement with
the reversed phase high performance liquid chromatography
analysis of substrate turnover by SARS-CoV Mpro, where s01 and13692 | Chem. Sci., 2021, 12, 13686–13703s02 display fast turnover; s10, s11 and s06 manifest medium
turnover; and the rest (s09, s08, s04, s03, s05, s07) show slow
turnover.44 Both of our MS studies on SARS-CoV-2 Mpro indicate
that s02 consistently displayed slower turnover than s11.
Previous reports on SARS-CoV Mpro have shown evidence for
cooperativity between subsites during substrate binding, in
particular during autocleavage of the Mpro C-terminal site (s02),
where the Phe at P2 induces formation of the S30 subsite to
accommodate the P30 Phe residue.55 SARS-CoV-2 Mpro substrate
s02 has a Phe at P2, but not at P30 (Fig. 1a). The absence of a Phe
at the P30 position may in part explain the reduced activity of
SARS-CoV-2 Mpro for s02 relative to s01, compared to the same
pair in SARS-CoV Mpro.44
The observed turnover of all 11 SARS-CoV-2 cleavage-site-
derived peptides by Mpro is consistent with our atomistic
models, where the peptides remain bound in the active site
during MD simulations and where the scissile amide carbonyl
remains well-positioned in the oxyanion hole (e.g., HB 8 in
Fig. 3) for reaction initiation. The stability of the Mpro–peptide
interactions involving the S2 and S1 subsites, as well as
backbone–backbone HBs 2, 3, 10 and 11, could explain the
observation using non-denaturing MS of complexes of Mpro
with products—because of slow product dissociation. Never-
theless, we envisage that the order of substrate turnover rates
is likely determined by various factors, including peptide
conformations, the inuence of the P2 and P10 residues on the
catalytic dyad (as highlighted by the BigDFT analysis),
entropic effects, and rates of product dissociation, all of
which prompt ongoing experimental and computational
investigations.
3. In silico mutational analysis of
substrate peptides enables peptide
inhibitor design
Building on insights gained from our binding studies of SARS-
CoV-2 Mpro and the 11 SARS-CoV-2 polypeptide substrate
sequences, we designed peptides that could bind more tightly
than the native substrates. We quantied the per-residue
energetic contributions of these sequences to the overall
binding in the Mpro active site and proposed substitutions that
would increase affinity. We hypothesised these peptides would:
(a) behave as competitive inhibitors, and (b) provide counter-
points for comparison with natural substrates, shedding light
on requirements for Mpro binding and, perhaps, turnover.
3.1 In silico alanine scanning and predictive saturation
variation scanning
We used the interactive web application BAlaS to perform
Computational Alanine-Scanning mutagenesis (CAS) using
BudeAlaScan56 and the BUDE_SM algorithm57 for Predictive
Saturation Variation Scanning (PreSaVS).58 Both are built on the
docking algorithm BUDE,59 which uses a semi-empirical free
energy force-eld to calculate binding energies.60 To identify key
binding interactions of the natural substrate peptides to Mpro,
the 11 substrate:Mpro complexes were rst subjected to CAS© 2021 The Author(s). Published by the Royal Society of Chemistry

























































































View Article Onlineusing BAlaS. By sequentially substituting for alanine, the ener-
getic contribution of each substrate residue to the overall
interaction energy between the singly mutated peptide andMpro
is calculated using:
DDG ¼ DGAla  DGwt
where DGwt is the interaction energy between the peptide and
Mpro, and DGAla is the interaction energy for the peptide with
a single alanine mutation at a given position. The more positive
the value for each residue, the greater the contribution from
that substrate residue to binding. This method was used later to
evaluate potential inhibitor peptides.
Having identied residues contributing most to the binding
energy of the natural Mpro substrates, each of the sequences was
subjected to PreSaVS using the BUDE_SM algorithm. This
sequentially substitutes each substrate residue with a range of
residues (D, E, F, H, I, K, L, M, N, Q, R, S, T, V, W and Y).
BUDE_SM calculates the DDG ¼ DGwt  DGmut for the binding
interaction of each, entire, singly mutated peptide with Mpro.
Substitutions predicted to improve binding over wildtypeFig. 8 BUDE_SM PreSaVS for the P2 position. (a) Heat-map for
BUDE_SM PreSaVS saturation mutagenesis at P2, showing the DDG ¼
DGwt  DGmut value calculated for each substitution and each Mpro
substrate. Mutations predicted to improve peptide binding have
a positive DDG and are greener; those disfavouring binding are in red.
(b) The summed DDG values for each residue type substituted at P2.
© 2021 The Author(s). Published by the Royal Society of Chemistrysequences have a positive DDG. Fig. 8 shows an example of the
BUDE_SM PreSaVS results for all the P2 substitutions for the 11
substrate peptides (normally Leu, Phe, or Val in the 11
substrates). The most positive results suggest that Phe, Trp and
Tyr favour increased predicted affinity at the P2 position
(Fig. 8b). However, although Tyr generally increased the pre-
dicted binding affinity (DDGsum ¼ 68.8 kJ mol1), it was not
considered for substitution at P2 due to its negative effect at this
position in s11 (scoring 18.9, Fig. 8a). Candidate residues for
each position, from P6 to P50, were shortlisted similarly based
on those with the best total, and the fewest unfavourable,
scores.
In addition to the computed DDG values, we considered the
propensity of each residue to promote an extended conforma-
tion. All bound substrates are largely extended, so entropic
penalties may be avoided if inherently extended conformations
could be favoured in the designed peptide. Thus, the best b-
forming (and therefore least a-forming) residues from the rst
triage were selected (Fig. 9a).61 We also considered solubility.
This was achieved by limiting the number of hydrophobic
residues in each designed peptide and ensuring a net positive
charge (except p14, which was neutral).Fig. 9 BAlaS-guided design of tight-binding peptides. (a) Propensity
scale of each amino acid to form an a-helical peptide conformation.
(b) Sequences of designed peptides p12–p16. Scatter plots with pre-
dicted BAlaS DDG ¼ DGAla  DGwt values on substitution to alanine for
each residue of (c) the 11 Mpro natural substrates and (d) designed
peptides based on these. The more positive the value, the greater the
contribution made by the sidechain to the overall binding energy. (e)
The BAlaS DDGSum comparing values between complexes of M
pro with
substrate and designed peptides as a proxy for predicting relative
binding affinity (larger score ¼ tighter binder).
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Fig. 10 IC50 of designed peptides against M
pro with varied substrate
concentrations. IC50s for (a) p12, (b) p13, (c) p15, (d) p16, (e) 15-mer
control peptide and (f) ebselen with 2 mM, 10 mM, 20 mM and 40 mM of
substrate peptide s01. IC50 values were calculated from technical
duplicates (Table S3.2†). See Experimental Section S1.8† for assay
details.

























































































View Article Online3.2 Designed peptide sequences
Employing the criteria described above, ve new peptides, p12–
p16, were designed (Fig. 9b). Comparison of the computed DDG
values for s01–s11 (Fig. 9c) and p12–p16 (Fig. 9d) reveals that
substitutions at the P sites provide only occasional, moderate
improvements to binding energy over the corresponding
substrate P sites, with the notable exception of P2, which can
accommodate Trp, Phe or Lys. These results agree with the HB
analysis, which predicts that the sidechains of residues that are
on the N-terminal side of the cleavage site (P sites) contribute
more to binding than C-terminal, P0 sites. The most striking
difference between substrates and designed peptides is in this
P0 region, where the predicted binding energy contributions for
the designed peptides exceed those of the substrates, an
advantage that is distributed over most of the designed P0
positions.
The nal step in design was to assess the relative binding
affinities of the substrates and designed peptides. Hence the
summed DDGs (Fig. 9e) provide a proxy for the binding energies
(BAlaS)62 for the substrates and designed peptides with Mpro.
The substrate:Mpro complexes are stabilised by an average of
46.5 kJ mol1, whereas the designed-peptide:Mpro complexes
are predicted to have, in some cases, double the interaction
stability of the substrates, with an average of 96.0 kJ mol1. The
full analysis is in the ESI le SI_BAlaS_BUDE_SM_12-04-
2021.xlsx.†3.3 Synthesis and analysis of designed peptides
To test the designed sequences, p12, p13, p15 and p16 were
synthesised with a carboxyl-amide C-terminus by solid phase
synthesis. Their Mpro inhibitory activity was determined by
dose–response analysis (Table 1) using SPE MS, monitoring
both substrate s01 (1191.68 Da) depletion and N-terminally
cleaved product (617 Da) formation. Ebselen which reacts
multiple times withMpro63 was used as a standard (IC50¼ 0.14
0.04 mM; Fig. 10).
All four designed peptides manifested similar potency with
IC50 values ranging from 3.11 mM to 5.36 mM (Table 1 and
Fig. S3.1†). Strikingly, despite the presence of Gln at P1 in all the
designed peptides assayed, no evidence for hydrolysis was
observed by SPE MS. This observation was supported by LCMS
of the peptides incubated overnight with Mpro (Fig. S3.2†). We
probed the inhibition mode of the designed peptides by
monitoring changes in IC50 while varying the substrate
concentration (2 mM, 10 mM, 20 mMand 40 mMTSAVLQYSGFRK-Table 1 Designed peptides inhibit Mpro in a dose-dependent manner.
The assay conditions were 0.15 mMMpro, 2 mM s01 in 20mMHEPES, pH
7.5, and 50 mM NaCl
Peptide IC50/mM Hill slope
p12 5.36  2.17 1.25  0.06
p13 3.11  1.80 0.94  0.09
p15 5.31  1.08 1.17  0.16
p16 3.76  0.51 1.19  0.16
13694 | Chem. Sci., 2021, 12, 13686–13703NH2 s01; Km  14.4 mM).63 The results indicated a linear
dependency between substrate concentration and IC50 values
(Fig. 10a–d). This was not observed with a control 15-mer
peptide or ebselen (Fig. 10e and f). Analysis of the data by the
procedure of Wei et al.64 implies competitive inhibition
(Fig. S3.3 and Tables S3.1, S3.2†). By contrast, the same analysis
for ebselen did not support competitive inhibition, consistent
with MS studies showing it has a complex mode of inhibition.63
Three of the synthesised peptides—p12, p13, and p15—have
a Trp at P2 (Fig. 9b) while the other, p16, has a Lys at P2. The 11
Mpro substrates all have hydrophobic residues (Leu, Val or Phe)
at P2 (Fig. 1a). To investigate if the nature of the hydrophobic P2
residue, or the hydrophilic nature of the Gln at P1, alters the
interaction of the peptide and hence its reactivity at the active
site, we synthesised p13-WP2L, s01-LP2W, and s01-QP1W.
There was no evidence for cleavage of p13-WP2L or s01-
QP1W. However, s01-LP2W underwent partial cleavage (12.6 
4.5)% aer overnight incubation. These results suggest that the
presence of a Trp at P2 hinders catalytically productive binding,
at least with these peptides, and that other residues (including
the P10 and P20 residues) play roles in orienting the substrates
for cleavage (vide infra).
We then used non-denaturing protein MS to study enzyme–
substrate/product/inhibitor complexes simultaneously with
turnover. Complexes between Mpro dimer and p12 and p13
were observed, together with the uncomplexed Mpro dimer in
the protein region of the mass spectra. No binding was
observed for p15 and p16, due to relatively high noise in that
m/z region. None of the designed peptides were cleaved by
Mpro, as recorded in the peptide region. As a control, s01 was© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 11 Non-denaturing MS analysis of designed peptides binding to
the Mpro dimer. Inhibitor binding from non-denaturing MS showing
normalized intensity in them/z region around the 14+ and 15+ charge
states of the Mpro dimer. (*) indicates unbound Mpro dimer. (a) 5 mM
Mpro solution; (b) 4-fold excess of p13 relative to the Mpro dimer; ‘P’
indicates sequential binding of p13 peptides to Mpro in the 15+ charge
state (red) and 14+ state (blue); (c) 16-fold excess of p13; (d) 16-fold
excess of p13 and 4-fold excess of s01; hash (#) indicates sequential
binding of s01-cleavage products (note: the resolution is not sufficient
to distinguish between the N- and C-terminal fragments; some non-
specific binding of p13 is also observed in (c) and (d) due to the high
concentration of the peptide).
Fig. 12 Binding of P2 Trp in the designed peptides. Conformations
adopted by the P2 Trp sidechain (cyan sticks; non-polar hydrogens
omitted for clarity) in p12 and p13 (grey ribbon) observed during
explicit and implicit solvent MD simulations, showing representative
structures obtained by RMSD clustering. His-41, Cys-145 and Asp-187
are shown in magenta. See Fig. S3.13† for cluster populations formed
during MD. For each peptide, conformations are displayed in
decreasing order of occurrence (above 10%).

























































































View Article Onlineadded to the protein/inhibitor mixtures; for all the inhibitors,
turnover of s01 was observed aer 3 min incubation. Deple-
tion of s01 was 95%, 91%, 70% and 78% in the presence of
p12, p13, p15 and p16, respectively, with an 8-fold excess of
inhibitor over Mpro, versus >98% depletion for the Mpro/s01
mixture without the inhibitor. In the protein region of the
mass spectra, complexes between Mpro dimers and the s01-
cleavage products were observed in the presence of p13, but
the abundance of these complexes was lower than the abun-
dance of Mpro/p13 complexes (Fig. 11). These results validate
the above-described evidence that the peptide inhibitors both
bind and competitively inhibit Mpro.Fig. 13 QM contact interaction graph for p13 and Mpro. Interactions
are computed using ensemble-averaged results of MD snapshots with
the BigDFT code.503.4 Understanding the basis of SARS-CoV-2 Mpro inhibition
by the designed peptides
3.4.1 Modelling of the designed peptides.Modelling of p12
and p13 shows that both bind stably at the active site duringMD
simulation (Fig. S3.4–S3.8†). Like the natural substrates, key
HBs form with Glu-166, Thr-26, Thr-24, and the oxyanion hole-
contributing Cys-145 (Fig. S3.9–S3.11†). However, HBs involving
the P1-Gln sidechain of p12 and p13 showed greater variability.
The favourability of the P2 Trp mutation, as predicted by the
BAlaS scores, prompted us to investigate its binding. In line
with the plasticity observed at S2, a variety of conformations are
observed during MD simulations at this position, showing
varying degrees of immersion in S2 (Fig. 12 and S3.12, S3.13†).
Similar results were obtained using iMD-VR (Fig. 12).
Analysis of the conformations of the most populated cluster
from MD using Arpeggio-generated hydrophilicity maps© 2021 The Author(s). Published by the Royal Society of Chemistry(Fig. S3.14†) reveals that the P2 Trp is more deeply buried within
S2 than the native P2 residues in the natural substrates, forming
more than double the number of hydrophobic contacts in the
cases of p12 and p13. Some conformations involve the indole
ring p–p-stacking, or hydrogen-bonding via its indole N–H,
with the catalytic His-41 sidechain, forming an extended HB
network (Fig. 12). It is possible that these interactions may
hamper the ability of His-41 to deprotonate Cys-145 at the start
of peptide hydrolysis, which could be tested using QM/MMChem. Sci., 2021, 12, 13686–13703 | 13695

























































































View Article Onlinecalculations. Interestingly, DFT-based interaction analysis
reveals that one of the slowest turnover substrates, s05 (Fig. 5),
and inhibitor p13 (Fig. 13), share similar short-range interac-
tion networks.
3.4.2 Comparative peptide docking. To investigate the
ability of the Mpro subsites to recognise residues in the designed
sequences, AutoDock CrankPep (ADCP) was used (Table
S3.3†).65 A trial was performed by redocking s01 into the H41A
SARS-CoV Mpro structure originally complexed with s01 (PDB
entry 2q6g).37 ADCP successfully positioned the peptide mostly
correctly in its top solution, with the Ca positions from P5 to P10
deviating by less than 1 Å (Table S3.4 and Fig. S3.15†). Devia-
tions increased up to 16 Å at P50 as the peptide coiled up in the
P0 positions, but this is deemed acceptable since the S0 subsites
are less well dened, as discussed earlier.
Following the promising redocking results with ADCP, s01–
s11, p12, p13, p15, and p16 were docked with an Mpro structure
originally complexed with the N3 inhibitor (PDB entry 7bqy; 1.7
Å resolution).2 Substrate-docked structures were found to have
the P4 and P2 residues correctly positioned in their corre-
sponding S4 and S2 pockets (Table S3.5†). From P1 to P50 the
poses were more variable, with some peptide backbones turning
through S1 rather than continuing an extended conformation,
likely due to the less well-dened S0 subsites (Fig. S3.16†). For
the designed peptides, by contrast, docking appeared less
successful (except p16), with none of the top 10 solutions
positioning the peptide in the manner observed in our MD
simulations (Fig. S3.17†). The S2 pocket in 7bqy binds the Leu
sidechain of N3 and is probably too shallow to accommodate
the larger Trp sidechain, given the assumption of a rigid
receptor in ADCP docking. Hence, the four designed peptides
were also docked to the C145A Mpro structure in complex with
the s02 cleaved product (PDB entry 7joy; 2 Å resolution),66 which
has a deeper S2 pocket that binds the P2 Phe sidechain in s02.
Interestingly, for both p12 and p16, the top docked solution
matched our design more closely (Table S3.6 and Fig. S3.18†).
Docking of p13 and p15 was challenging, possibly due to the
difficulty of recognising a larger Leu (p13) or Ile (p15) residue in
the S4 pocket, which originally accommodated a Val sidechain.
This highlights the ability of the Mpro active site to adapt when
binding to different substrates or inhibitors.Fig. 14 Clustering of XChem active site-binding fragments. Surface of
the x0830-bound Mpro structure (white surface) and the top 5 most
populated fragment clusters using a clustering threshold of 0.5. (a)
Cluster 1 fragments tend to occupy S10 (green); (b) clusters 2 (cyan) and
3 (yellow) tend to span S10 and S2; (c) clusters 4 (lilac) and 5 (pink) tend
to occupy S2 and S1. (d) Close-up of cluster 5. Green dotted lines
indicate the two key HBs between the fragment carbonyl oxygen and
the backbone nitrogen of Glu-166 (HB 3, Fig. 3), and between the His-
163 N3 and the heterocyclic nitrogen of the fragment (HB 6, Fig. 3). (e)
Overlay of the P4–P10-truncated structure of peptide inhibitor p13
(grey) from an MD snapshot and cluster 5 binder x0678 (pink), with the
x0678 co-crystal structure (white surface).3.5 Summary – designed peptides
We used in silico Predictive Saturation Variation Scanning to
design peptides that were shown in vitro to inhibit Mpro
competitively. Structures of p12 and p13 generated by both
iMD-VR docking and comparative modelling behaved similarly,
in terms of HB formation and peptide backbone RMSD and
RMSF, when performing MD. These studies highlight how the
S2 subsite can adapt its size and interaction network via
induced t to accommodate different substrate or inhibitor P2
residues.
Notably, while these models suggested similarly stable
binding modes as seen with the natural substrates, turnover of
the inhibitor peptides by Mpro was not detected. This may relate
to the more favourable predicted binding affinity of the13696 | Chem. Sci., 2021, 12, 13686–13703designed peptide–Mpro complexes, both in terms of higher
overall interaction energies, and greater contribution of the P0
residues than in the natural substrates. Our MD simulations
suggest it is also possible that the larger P2 residue prevents the
catalytically vital His-41 from adopting a reactive conformation
(Fig. 12).4. Mpro–ligand interaction analysis
Having elucidated how Mpro recognises its substrates and our
designed peptide inhibitors, we hypothesised that this might be
reected in the extensive small-molecule inhibitor work onMpro
and could, in turn, be exploited for the design of novel small-
molecule inhibitors and peptidomimetics. We explored
whether ligands sharing the same contacts as the natural
substrates could lead to better inhibitory activity. We analysed
all 91 X-ray structures of small molecule fragments complexed© 2021 The Author(s). Published by the Royal Society of Chemistry

























































































View Article Onlinewith Mpro obtained by high-throughput crystallographic
screening at Diamond's XChem facility,35 as well as the dataset
of 798 designed inhibitors and 245 crystal structures obtained
from the COVID Moonshot project.36 We analysed them by
investigating their protein–ligand interaction patterns.
4.1 Interaction analysis of XChem fragments
We separated fragments into non-active-site binders (25 frag-
ments) and active-site binding/likely-substrate competing
molecules (66 fragments; Fig. S4.1†). A ngerprint bit-vector
was constructed for every active-site binding fragment, with
each bit denoting the presence or absence of a given interaction
with Mpro residues, and used for clustering fragments by their
interaction ngerprint Tanimoto similarity,67 with 1 corre-
sponding to identical contacts, and 0 to no shared contacts
(Fig. 14, S4.2–S4.5 and Table S4.1†). All the fragments and
ligands in clusters 1 and 2 (except x0397, x0978 and x0981) are
covalently bound to Cys-145. As a result, a highly conserved
binding mode is observed for the carbonyl-containing covalent
warheads (e.g., chloroacetamides), where the carbonyl oxygen
binds into the oxyanion hole between residues Gly-143 and Cys-
145, mimicking substrate HBs 8 and 9 (Fig. 3). Cluster 5 stands
out as the only major cluster with fragments that bind deeply
into S1, one of the main conserved contacts identied in all
substrates. Cluster 5 shows a distinct binding motif primarily
driven by: (i) hydrogen bonding between a carbonyl oxygen on
the fragment and the Glu-166 backbone NH-group; and (ii)
a strong polar interaction between His-163 and the fragment.
Notably, the protonation of the imidazole of His-163 appears to
depend on the fragment.
Overall, the primary functionality that facilitates interaction
with His-163 is the nitrogen-containing heterocycle present in
almost all ligands in cluster 5 (Fig. 15); the exception is x0967,
which forms the His-163 HB via its phenol oxygen. Such
heterocycles are well suited to replace the substrate P1 Gln
sidechain by mimicking its HB donor/acceptor abilities. In
addition, most cluster 5 binders also extend into the hydro-
phobic S2 pocket, although there is no clear preference in
functional group at S2. This agrees with our plasticity analysis,
which shows that S2 can accommodate a large variety of func-
tional groups (Fig. S4.4†). As seen in the overlap of peptideFig. 15 Structures of the cluster 5 XChem compounds. Note the
prevalence of nitrogen-containing heterocycles, and the phenol-
containing derivative x0967.
© 2021 The Author(s). Published by the Royal Society of Chemistryinhibitor p13 and cluster 5 representative x0678 (Fig. 14e), the
binding modes of both inhibitors in the S1 and S2 subsites are
very similar, with both forming HBs to His-163 (HB-6) and Glu-
166 (HBs 2 & 3) and binding deep in the S2 pocket. In addition,
all cluster 5 ligands (Fig. 15) contain an amide or urea linker
between the P1 and P2 binding groups making them interesting
building blocks for the development of peptidomimetics.
The interactions between the fragments, substrates, and
peptide inhibitors with Mpro were analysed by employing
linear scaling DFT. Using short-range (Econt) DFT interactions
with Mpro as a “descriptor” for clustering, a cluster containing
both the substrates and the cluster 5 compounds (x0107, x0434,
x0540, x0678, x0967 and x1093) was identied (Fig. S4.6†). This
cluster also included compounds x0426, x0946, x0195, x0995,
x0104, x0874, x1077, x0161 and x0397. This agnostic analysis,
based on quantum mechanical descriptors, provides further
conrmation and a powerful alternative to evaluate compounds
of differing sizes in biomolecular complexes.
To test whether cluster 5 inhibitors are promising building
blocks for optimization, we identied all assayed and crystal-
lized cluster 5 binders in the COVID Moonshot project data-
base36 as of 11th Jan 2021 and analysed them using Arpeggio.
Compounds were deemed cluster 5 inhibitors if they shared at
least 70% of the contacts identied in fragment cluster 5. We
observed that cluster 5 inhibitors have a signicantly higher
proportion of “strong” binders, classied as IC50 < 99 mM (85%
of cluster 5 compounds), unlike the rest of the Moonshot
project database (67%). Closer analysis can be found in Section
S4.2 and Fig. S4.7.† In summary, based on Arpeggio and BigDFT
contact analysis and reported assay data, cluster 5 binders are
promising building blocks for substrate-competing inhibitor
design.4.2 Covalent docking of COVID Moonshot compounds
To accommodate induced t and create high quality poses of
covalent inhibitors for future optimisation, we selected 540
covalently-reacting compounds from 10 001 Moonshot-
designed compounds and docked them using AutoDock4 68
into the Mpro structure of the corresponding covalent “inspira-
tion” fragments.36 We generated an interaction TanimotoFig. 16 Analysis of fragment and designed compounds from the
Moonshot project. Workflow used to identify promising fragments and
guide novel designs.
Chem. Sci., 2021, 12, 13686–13703 | 13697

























































































View Article Onlinedistance matrix as described earlier, and analysed the ability of
the procedure to recapitulate the binding mode of the parent
fragment. The normalized shape and pharmacophoric overlap
(SuCOS69) of the lowest energy pose of the highest populated
cluster for each Moonshot compound was compared with the
inspiration covalent XChem fragment (Fig. S4.8†). When
controlling for the smallest maximum common substructure
(MCS) that encompasses the covalent warhead and one addi-
tional atom in the compound, 379 designs remain, 132 (34.8%)
of which adopted the bindingmode of the inspiration fragment.
Given the high similarity between the fragments and docked
designs, it is likely that these binding modes are more repre-
sentative of the actual binding mode. A summary of the work-
ow is shown in Fig. 16.
In summary, our covalent docking method is more likely to
identify the correct binding mode when substantial overlap
exists between the inspiration fragment and designed
compound beyond the covalent warhead (Section S4.3 and
Fig. S4.8, S4.9†). This generated 132 high quality docked poses
which serve as inspiration for future inhibitor design and wereFig. 17 Docking informs novel inhibitor design. HBs between Mpro (mage
docked pose of FOC-CAS-e3a94da8-1 (green and greenish-yellow) wit
5RER; 1.88 Å resolution).35 Derivatisation of x10789 into the oxyanion ho
x0830 (highlighted greenish-yellow). (b) Docked pose of Pfizer's Phase I c
6XHM; 1.41 Å resolution).71 PF-07321332 (cyan) is covalently attached to
the ‘combination’ of x10789 and x0830, namely the double HB to the ba
hydrophobic interactions in the S2 subsite. (c) Structures of Moonshot d
x10789, and inhibitor PF-07321332.
13698 | Chem. Sci., 2021, 12, 13686–13703used in our proposals for compound derivatisation in Section
4.3. All poses of the 540 docking runs are available at https://
github.com/gmm/SARS-CoV-2-Modelling.4.3 Implications for future inhibitor design
We compared the interactions of the cluster 5 binders with
those in the substrates, peptide inhibitors, and XChem frag-
ments. Interestingly, unlike the peptides, almost none of the
cluster 5 binders interact with the oxyanion hole. The only
cluster 5 compounds where this contact is made are a series of
covalent inhibitors, none of which showed promising potency
(Fig. S4.11†). An exhaustive search of Moonshot structures
showed that at the time of the analysis, no non-covalent
inhibitor has ever been tested that includes both the typical
cluster 5 bindingmode while also being able to interact with the
oxyanion hole.
We compared the structures of the top 10 compounds in
cluster 5 (part of the dataset analysed in Section 4.1) to the
docked structures of covalent Moonshot designs (Section 4.2).nta) and the ligands are shown as dotted yellow lines. (a) Overlay of the
h the crystal structure of x10789 (pink) on the Mpro surface (PDB entry
le could be achieved by attaching a methylene amide group present in
ovalent inhibitor PF-07321332, covalently docked into Mpro (PDB entry
Cys-145. The docked PF-07321332 adopts the same major contacts as
ckbone of Glu-166, the HB to His-163 in the S1 subsite, and a series of
esigned compound FOC-CAS-e3a94da8-1, crystallographic fragment
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 18 Summary of the research and results obtained in this work.

























































































View Article OnlineTwo compounds—FOC-CAS-e3a94da8-1 and MIH-UNI-
e573136b-3—were selected based on their high normalized
SuCOS overlap with their inspiration fragments, strongly sug-
gesting that their docked binding modes reect the actual
poses.70 Both compounds bind into the oxyanion hole as well as
into S1 and S2, providing a clear opportunity for extension of
the cluster 5 binders (Fig. S4.12†).
Most cluster 5 binders place the aromatic heterocycle into
the S1 site and the carbonyl oxygen of the amide linker bonds to
Glu-166 (Fig. 17). The position of this amide nitrogen overlays
perfectly with the ring amine present in the docked compound
FOC-CAS-e3a94da8-1. Thus, extension of cluster 5 binders into
the oxyanion hole could be achieved by adding a substituent at
the amide nitrogen. A promising candidate for extension is
x10789, which makes a HB with the backbone oxygen of Glu-166
(Fig. 17a) and mimics the non-prime side binding mode of
peptide inhibitor p13 (Fig. 14e), even binding into the S4 site via
its b-lactam ring (Fig. 17a). Additional expansion into the oxy-
anion hole and S10 through the amide linker could yield
a powerful peptidomimetic inhibitor, combining protein
interactions observed for the substrates, peptide inhibitors and
small molecule fragments.
When comparing interactions exhibited by cluster 5 binders
(Glu-166, His-163) or covalent fragments (Gly-143, Cys-145) with
the contacts present in the docked structure of the recently
published Phase 1 clinical trial candidate PF-07321332 by Pzer
(Fig. 17b),13,14 a nearly identical interaction pattern to the cluster
5 binding motif is observed. However, note that for reacted PF-
07321332, AutoDock4 was unable to place the negatively
charged azanide nitrogen in the oxyanion hole, which is the
expected position given its similarity to related warheads
previously docked (Fig. S4.9†).© 2021 The Author(s). Published by the Royal Society of Chemistry5. Conclusions
A wealth of crystal structures of SARS-CoV-2 Mpro is available,
including hundreds with ligands. There is thus the question of
how best to use this static information to help develop Mpro
inhibitors optimised in terms of efficacy and safety for COVID-
19 treatment. The dimeric nature of Mpro, coupled with its
multiple substrates, makes it challenging to understand the
structural and dynamic features underpinning selectivity and
catalysis, as is the case with many other proteases. Such an
understanding is, of course, not essential to develop medicines,
as shown by work with other viral proteases. However, it may
help improve the quality of such medicines and the efficiency
with which they are developed. It will also lay the foundation for
tackling anti-COVID-19 drug resistance—a challenge we will
likely encounter as experience with the HIV global pandemic
implies. The scale of global efforts on Mpro makes this system
an excellent model for collaborative efforts linking experimental
biophysics, modelling, and drug development (Fig. 18).
The results of our combined computational studies,
employing classical molecular mechanics and quantum
mechanical techniques, ranging from automated docking and
MD simulations to linear-scaling DFT, QM/MM, and iMD-VR,
provide consistent insights into key binding and mechanistic
questions. One such question concerns the protonation state of
the ‘catalytic’ His-41/Cys-145 dyad, an important consideration
in the rates of reaction of covalently linked Mpro inhibitors
which ultimately relates to their selectivity and potency. Our
results indicate that a neutral catalytic dyad is thermodynami-
cally preferred in Mpro complexed with an unreacted substrate,
justifying the neutral state for MD simulations. A more reactive
thiolate anion may be deleterious to the virus, as it will beChem. Sci., 2021, 12, 13686–13703 | 13699

























































































View Article Onlinesusceptible to reaction with electrophiles. Importantly, analysis
of the active site suggests that the precise mechanism of proton
transfer in the His-41/Cys-145 dyad involves dynamic interac-
tions with other residues, including His-163, His-164, Asp-187,
and a water hydrogen bonded to the latter two residues and
His-41. Proton transfer may be considered a relatively simple
part of the overall catalytic cycle—these results thus highlight
how Mpro catalysis is likely a property of (at least) the entire
active site region, with a future challenge being to understand
motions during substrate binding, covalent reaction, and
product release.
The models we have developed of Mpro in complex with its 11
natural substrates provided a basis for analysis of key interac-
tions involved in substrate recognition and for comparison with
(potential) inhibitor binding modes. Notably, the P0 (C-
terminal) side of substrates appears to be much less tightly
bound than the P (N-terminal) side, where there is remarkable
consistency in the hydrogen bonding patterns across the
substrates. This difference may in part reect the need for the P0
side to leave (at least from the immediate active site region)
aer acyl–enzyme complex formation and prior to acyl–enzyme
hydrolysis. The tighter binding of the N-terminal P-side resi-
dues suggests these are likely more important in substrate
recognition by Mpro. This is also reected in potent inhibitors,
such as N3 and peptidomimetic ketoamides,2,4 which predom-
inantly bind in these non-prime S subsites. The development of
S-site-binding inhibitors may also reect the nature of the
substrates used in screens leading to them, which typically
comprise an S-site binding peptide with a C-terminal group
enabling uorescence-based measurement. Our results imply
that there is considerable scope for developing inhibitors
exploiting the S0 subsites, or both S and S0 subsites, though
relatively more effort may be required to obtain tight binders
compared to targeting the S subsites.
Consistent with prior studies, our work highlights the crit-
ical role of the completely conserved P1 Gln residue in
productive substrate binding and analogously in inhibitor
binding. However, the nature of the P2/S2 interaction is also
important in catalysis. In the natural substrates (Fig. 1), the P2
position is Leu in 9 of the 11 substrates, Phe in s02 (which
displays medium turnover efficiency), and Val in s03 (which is
a poor substrate). Our results show that the S2 subsite plays
a critical role in recognition and inhibition. S2 is highly plastic
(Fig. 6 and S4.4†) and can accommodate a range of different
sidechains, including larger groups, though not necessarily in
a productive manner. The observation that substrates with a P2
Leu vary in efficiency reveals that interactions beyond those
involving P1 and P2 are important, reinforcing the notion that
(likely dynamic) interactions beyond the immediate active site
are important in determining selectivity both in terms of
binding and rates of reaction of enzyme–substrate complexes.
Notably, the results of computational alanine scanning
mutagenesis followed by design, aimed at identifying peptides
that would bind more tightly than the natural substrates, led to
the nding that substitution of a Trp at P2 ablates hydrolysis
creating an inhibitor. The observations with peptide inhibitors
of Mpro have precedence in studies with other nucleophilic13700 | Chem. Sci., 2021, 12, 13686–13703proteases, including the serine protease elastase, showing that
substrate substitutions away from the scissile P1/P0 residues can
cause inhibition.72,73 There is thus scope for the extensive
development of tight binding peptidic and peptidomimetic
Mpro inhibitors for use in inhibition and mechanistic/
biophysical studies, with the Trp at P2 of the peptide inhibi-
tors being a good point for SAR exploration, potentially by (i)
replacement of the indole hydrogen with suitable alkyl or aryl
substituents; (ii) introduction of substituents with different
stereoelectronic properties at C-2 or C-5 of the indole ring; or
(iii) cyclization by the insertion of a methylene group linking
position 2 of the indole ring to the a-nitrogen of Trp itself.74
Finally, the combined analysis of interactions involved in
substrate binding and extensive structural information on
inhibitor/fragment binding to Mpro enabled us to identify
a cluster of inhibitors whose interactions relate to those
conserved in substrate binding (e.g., involving the Glu-166
backbone, His-163 sidechain, and/or the oxyanion hole
formed by the Cys-145 and Gly-143 backbones). Building out
from these ‘privileged’ interactions (Fig. 17) might be a useful
path for inhibitor discovery. Indeed, an Mpro inhibitor now in
clinical trials13,14 exploits the same ‘privileged’ interactions that
we identied. We hope the methods and results that have
emerged from our collaborative efforts will help accelerate the
development of drugs for treatment of viral infections, and
particularly COVID-19.
6. Methods
A detailed description of the experimental and computational
methods employed in this work is provided in the ESI.†
Data availability
Structures, input les, underlying data, and source code are
publicly available on GitHub at https://github.com/gmm/SARS-
CoV-2-Modelling.
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P. Ábrányi-Balogh, J. Brandão-Neto, A. Carbery, G. Davison,
A. Dias, T. D. Downes, L. Dunnett, M. Fairhead, J. D. Firth,
S. P. Jones, A. Keeley, G. M. Keserü, H. F. Klein,
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